ClinicalTrials.gg

Program

CLDN6 RNA-LPX Vaccine

Its studies are mostly in Testicular Germ Cell Tumor, led by BioNTech.

Furthest: phase 2, since Apr 16, 20251 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BioNTech10 open or runningphase 2since Apr 16, 2025Apr 16, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 16, 2025First study: phase 2 study in Testicular Germ Cell TumorFirst studyNCT06940804

TargetBeta

CLDN6 →read by rule
“A RNA-lipoplex (RNA-LPX)-based cancer vaccine containing messenger RNA (RNA) encoding for the tumor-associated antigen (TAA) claudin 6 (CLDN6; CLDN-6), ”NCIt, by rule

Other programs on CLDN6

ProgramCompanyFurthest phaseStudies
ixotatug vedotinruletorl-biotherapeutics-llcphase 23
Anti-CLDN6/CD3 Bispecific Antibody XmAb541ruleXencorphase 12
Anti-CLDN6/Anti-CD3 Bispecific Antibody BGB-B455ruleBeOne Medicinesphase 11
Anti-Claudin 6 Antibody-drug Conjugate AT03-65ruleaxcynsis-therapeutics-pte-ltdphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06940804Testicular Germ Cell Tumor2WithdrawnJun 20420

How it is read

Names in the registry

  • “CLDN6 RNA-LPX”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.